Contact
Please use this form to send email to PR contact of this press release:
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
TO:
Please use this form to send email to PR contact of this press release:
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
TO: